Maravai Lifesciences Holdings, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Maravai LifeSciences reported a significant revenue decrease and net loss in 2025, driven by reduced CleanCap sales and substantial impairment charges, while implementing a major corporate realignment.
NASDAQ
10-K: Maravai LifeSciences Holdings Reports Fiscal Year 2024 Results; Announces Strategic Acquisitions
Maravai LifeSciences Holdings details its financial performance for 2024, highlighting challenges and strategic moves including acquisitions to bolster its nucleic acid production capabilities.
NASDAQ
Maravai LifeSciences Holdings, Inc. outlines its share structure, voting rights, and corporate governance policies in its latest 10-K filing, emphasizing anti-takeover provisions and management control.